This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Medway setup a state-of-the-art Heart Institute in Chennai
Ecolab’s continued leadership position on renowned sustainability indices demonstrates the company’s record of advancing sustainable growth
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Furthering cell therapy ambition across oncology and autoimmune diseases
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Subscribe To Our Newsletter & Stay Updated
